Literature DB >> 19887893

Parathyroid hormone accelerates decompensation following left ventricular hypertrophy.

Hyeseon Cha1, Hyeon Joo Jeong, Seung Pil Jang, Joo Yeon Kim, Dong Kwon Yang, Jae Gyun Oh, Woo Jin Park.   

Abstract

Parathyroid hormone (PTH) treatment was previously shown to improve cardiac function after myocardial infarction by enhancing neovascularization and cell survival. In this study, pressure overload-induced left ventricular hypertrophy (LVH) was induced in mice by transverse aortic banding (TAB) for 2 weeks. We subsequently evaluated the effects of a 2-week treatment with PTH or saline on compensated LVH. After another 4 weeks, the hearts of the mice were analyzed by echocardiography, histology, and molecular biology. Echocardiography showed that hearts of the PTH-treated mice have more severe failing phenotypes than the saline-treated mice following TAB with a greater reduction in fractional shortening and left ventricular posterior wall thickness and with a greater increase in left ventricular internal dimension. Increases in the heart weight to body weight ratio and lung weight to body weight ratio following TAB were significantly exacerbated in PTH-treated mice compared to saline-treated mice. Molecular markers for heart failure, fibrosis, and angiogenesis were also altered in accordance with more severe heart failure in the PTH-treated mice compared to the saline-treated mice following TAB. In addition, the PTH-treated hearts were manifested with increased fibrosis accompanied by an enhanced SMAD2 phosphorylation. These data suggest that the PTH treatment may accelerate the process of decompensation of LV, leading to heart failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19887893      PMCID: PMC2811821          DOI: 10.3858/emm.2010.42.1.006

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  25 in total

Review 1.  Negative regulators of cardiac hypertrophy.

Authors:  Stefan E Hardt; Junichi Sadoshima
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

2.  Left ventricular hypertrophy in end-stage renal disease.

Authors:  J D Harnett; P S Parfrey; S M Griffiths; M H Gault; P Barre; R D Guttmann
Journal:  Nephron       Date:  1988       Impact factor: 2.847

3.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

4.  Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis.

Authors:  Min-Sheng Chen; Fang-Ping Xu; Yan-Zhen Wang; Gui-Ping Zhang; Quan Yi; Hui-Qiu Zhang; Jian-Dong Luo
Journal:  J Mol Cell Cardiol       Date:  2004-10       Impact factor: 5.000

Review 5.  Regulation of parathyroid hormone secretion.

Authors:  S L Pocotte; G Ehrenstein; L A Fitzpatrick
Journal:  Endocr Rev       Date:  1991-08       Impact factor: 19.871

6.  The transcription factor Eya2 prevents pressure overload-induced adverse cardiac remodeling.

Authors:  Seung Hee Lee; Dong Kwon Yang; Bo Youn Choi; Young-Hoon Lee; Seon-Young Kim; Dongtak Jeong; Roger J Hajjar; Woo Jin Park
Journal:  J Mol Cell Cardiol       Date:  2009-01-14       Impact factor: 5.000

7.  Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.

Authors:  Masahiko Hoshijima; Yasuhiro Ikeda; Yoshitaka Iwanaga; Susumu Minamisawa; Moto-o Date; Yusu Gu; Mitsuo Iwatate; Manxiang Li; Lili Wang; James M Wilson; Yibin Wang; John Ross; Kenneth R Chien
Journal:  Nat Med       Date:  2002-07-22       Impact factor: 53.440

Review 8.  B-type natriuretic peptide levels: diagnostic and therapeutic potential.

Authors:  A Maisel
Journal:  Cardiovasc Toxicol       Date:  2001       Impact factor: 3.231

9.  Parathyroid hormone and left ventricular hypertrophy.

Authors:  F N Saleh; H Schirmer; J Sundsfjord; R Jorde
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

10.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.

Authors:  H A Rockman; R S Ross; A N Harris; K U Knowlton; M E Steinhelper; L J Field; J Ross; K R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

View more
  13 in total

1.  Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure.

Authors:  G Loncar; B Bozic; N Cvetinovic; H-D Dungen; M Lainscak; S von Haehling; W Doehner; Z Radojicic; B Putnikovic; T Trippel; V Popovic
Journal:  J Endocrinol Invest       Date:  2016-10-13       Impact factor: 4.256

2.  Correlation between serum parathyroid hormone levels and coronary artery calcification in patients without renal failure.

Authors:  Gang-Yong Wu; Bai-Da Xu; Ting Wu; Xiao-Ying Wang; Tian-Xiao Wang; Xiao Zhang; Xiao Wang; Yang Xia; Gang-Jun Zong
Journal:  Biomed Rep       Date:  2016-09-26

3.  Cinacalcet ameliorates cardiac fibrosis in uremic hearts through suppression of endothelial-to-mesenchymal transition.

Authors:  Min Wu; Ri-Ning Tang; Hong Liu; Ming-Ming Pan; Lin-Li Lv; Jian-Dong Zhang; Steven D Crowley; Bi-Cheng Liu
Journal:  Int J Cardiol       Date:  2013-12-07       Impact factor: 4.164

4.  Functional proteomic analysis reveals sex-dependent differences in structural and energy-producing myocardial proteins in rat model of alcoholic cardiomyopathy.

Authors:  Rachel L Fogle; Christopher S Hollenbeak; Bruce A Stanley; Thomas C Vary; Scot R Kimball; Christopher J Lynch
Journal:  Physiol Genomics       Date:  2011-01-18       Impact factor: 3.107

Review 5.  Coronary artery calcification in chronic kidney disease: An update.

Authors:  Tomasz Stompór
Journal:  World J Cardiol       Date:  2014-04-26

6.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

7.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

Review 8.  Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease.

Authors:  Peng Hu; Bo Hu; Jing Wang; Ling Lu; Yuan Han Qin
Journal:  Med Sci Monit       Date:  2011-06

9.  Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish.

Authors:  Jason R Becker; Rahul C Deo; Andreas A Werdich; Daniela Panàkovà; Shannon Coy; Calum A MacRae
Journal:  Dis Model Mech       Date:  2011-01-18       Impact factor: 5.758

10.  AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure.

Authors:  Chang Sik Park; Hyeseon Cha; Eun Jeong Kwon; Dongtak Jeong; Roger J Hajjar; Evangelia G Kranias; Chunghee Cho; Woo Jin Park; Do Han Kim
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.